Oruka Therapeutics annual current ratio
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Oruka Therapeutics Current Ratio Growth & History (ORKA)
Oruka Therapeutics's current ratio was 22.37 for fiscal 2025.
View full Oruka Therapeutics company overviewOruka Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 22.37 | −6.53 | −22.59% |
| 2024 | 2024-12-31 | 28.89 | −30.12 | −51.04% |
| 2023 | 2023-12-31 | 59.01 | 21.29 | +56.45% |
| 2022 | 2022-12-31 | 37.72 | 22.16 | +142.45% |
| 2021 | 2021-12-31 | 15.56 | 1.28 | +8.94% |
| 2020 | 2020-12-31 | 14.28 | 5.12 | +55.94% |
| 2019 | 2019-12-31 | 9.16 | 0.61 | +7.16% |
| 2018 | 2018-12-31 | 8.55 | 2.60 | +43.84% |
| 2017 | 2017-12-31 | 5.94 | −3.01 | −33.62% |
| 2016 | 2016-12-31 | 8.95 | −16.92 | −65.41% |
| 2015 | 2015-12-31 | 25.88 | 14.72 | +131.89% |
| 2014 | 2014-12-31 | 11.16 | −0.11 | −0.97% |
| 2013 | 2013-12-31 | 11.27 | 1.28 | +12.87% |
| 2012 | 2012-12-31 | 9.98 | 1.74 | +21.18% |
| 2011 | 2011-12-31 | 8.24 | 2.22 | +36.89% |
| 2010 | 2010-12-31 | 6.02 | — | — |
Oruka Therapeutics quarterly current ratio
Q4.10
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 38.51 | 11.10 | +40.47% |
| Q1 2026 | 2026-03-31 | 23.76 | −6.27 | −20.88% |
| Q4 2025 | 2025-12-31 | 22.37 | −6.53 | −22.59% |
| Q3 2025 | 2025-09-30 | 16.94 | −5.95 | −26.00% |
| Q2 2025 | 2025-06-30 | 27.42 | 0.81 | +3.03% |
| Q1 2025 | 2025-03-31 | 30.03 | 6.84 | +29.49% |
| Q4 2024 | 2024-12-31 | 28.89 | −30.12 | −51.04% |
| Q3 2024 | 2024-09-30 | 22.89 | −16.31 | −41.61% |
| Q2 2024 | 2024-06-30 | 26.61 | 1.17 | +4.59% |
| Q1 2024 | 2024-03-31 | 23.19 | −9.75 | −29.59% |
| Q4 2023 | 2023-12-31 | 59.01 | 21.29 | +56.45% |
| Q3 2023 | 2023-09-30 | 39.21 | 16.21 | +70.46% |
| Q2 2023 | 2023-06-30 | 25.44 | 8.47 | +49.96% |
| Q1 2023 | 2023-03-31 | 32.94 | 14.35 | +77.22% |
| Q4 2022 | 2022-12-31 | 37.72 | 22.16 | +142.45% |
| Q3 2022 | 2022-09-30 | 23.00 | 4.25 | +22.66% |
| Q2 2022 | 2022-06-30 | 16.97 | −0.57 | −3.25% |
| Q1 2022 | 2022-03-31 | 18.59 | −5.28 | −22.11% |
| Q4 2021 | 2021-12-31 | 15.56 | 1.28 | +8.94% |
| Q3 2021 | 2021-09-30 | 18.75 | −15.26 | −44.87% |
| Q2 2021 | 2021-06-30 | 17.54 | 8.82 | +101.22% |
| Q1 2021 | 2021-03-31 | 23.86 | 17.48 | +273.59% |
| Q4 2020 | 2020-12-31 | 14.28 | 5.12 | +55.94% |
| Q3 2020 | 2020-09-30 | 34.01 | 25.40 | +294.93% |
| Q2 2020 | 2020-06-30 | 8.71 | 0.10 | +1.22% |
| Q1 2020 | 2020-03-31 | 6.39 | −0.23 | −3.42% |
| Q4 2019 | 2019-12-31 | 9.16 | 0.61 | +7.16% |
| Q3 2019 | 2019-09-30 | 8.61 | 0.03 | +0.37% |
| Q2 2019 | 2019-06-30 | 8.61 | −0.83 | −8.83% |
| Q1 2019 | 2019-03-31 | 6.61 | −0.79 | −10.66% |
| Q4 2018 | 2018-12-31 | 8.55 | 2.60 | +43.84% |
| Q3 2018 | 2018-09-30 | 8.58 | 2.14 | +33.30% |
| Q2 2018 | 2018-06-30 | 9.44 | 2.83 | +42.83% |
| Q1 2018 | 2018-03-31 | 7.40 | −0.48 | −6.10% |
| Q4 2017 | 2017-12-31 | 5.94 | −3.01 | −33.62% |
| Q3 2017 | 2017-09-30 | 6.44 | −4.60 | −41.66% |
| Q2 2017 | 2017-06-30 | 6.61 | −9.14 | −58.03% |
| Q1 2017 | 2017-03-31 | 7.88 | −5.35 | −40.42% |
| Q4 2016 | 2016-12-31 | 8.95 | −16.92 | −65.41% |
| Q3 2016 | 2016-09-30 | 11.03 | −20.94 | −65.49% |
| Q2 2016 | 2016-06-30 | 15.75 | −16.94 | −51.81% |
| Q1 2016 | 2016-03-31 | 13.23 | 2.05 | +18.30% |
| Q4 2015 | 2015-12-31 | 25.88 | 14.72 | +131.89% |
| Q3 2015 | 2015-09-30 | 31.97 | 11.13 | +53.39% |
| Q2 2015 | 2015-06-30 | 32.69 | 16.52 | +102.15% |
| Q1 2015 | 2015-03-31 | 11.19 | −8.28 | −42.53% |
| Q4 2014 | 2014-12-31 | 11.16 | −0.11 | −0.97% |
| Q3 2014 | 2014-09-30 | 20.84 | −3.88 | −15.70% |
| Q2 2014 | 2014-06-30 | 16.17 | −11.37 | −41.29% |
| Q1 2014 | 2014-03-31 | 19.47 | 14.64 | +303.64% |
| Q4 2013 | 2013-12-31 | 11.27 | 1.28 | +12.87% |
| Q3 2013 | 2013-09-30 | 24.72 | 13.31 | +116.55% |
| Q2 2013 | 2013-06-30 | 27.54 | 20.76 | +305.87% |
| Q1 2013 | 2013-03-31 | 4.82 | −3.09 | −39.08% |
| Q4 2012 | 2012-12-31 | 9.98 | 1.74 | +21.18% |
| Q3 2012 | 2012-09-30 | 11.42 | 2.21 | +23.95% |
| Q2 2012 | 2012-06-30 | 6.79 | −1.01 | −12.95% |
| Q1 2012 | 2012-03-31 | 7.92 | — | — |
| Q4 2011 | 2011-12-31 | 8.24 | 2.22 | +36.89% |
| Q3 2011 | 2011-09-30 | 9.21 | — | — |
| Q2 2011 | 2011-06-30 | 7.80 | — | — |
| Q4 2010 | 2010-12-31 | 6.02 | — | — |
Oruka Therapeutics current ratio trends
Over the last five fiscal years, Oruka Therapeutics's current ratio increased from 14.28 to 22.37, a change of 8.09. The latest reported quarter, Q2 2026, shows 38.51.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Oruka Therapeutics source filings ↗Community posts
Oruka’s psoriasis study supports planned Phase 3 trials after strong skin clearance
Oruka ($ORKA) reported positive 16-week results for ORKA-001 in the randomized Phase 2b EVERLAST-B psoriasis study. Among 46 patients assigned the highest dose, 61% achieved complete skin clearance, compared with none of 47 placebo recipien ...
